Comparable stake leader
Jacob Safier
SEC ownership of T2 Biosystems, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001492674.
Disclosed value leader
CR Group L.P.
Comparable rows
2/19
Latest evidence
31 Dec 2024
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Jacob Safier
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 19
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Jacob Safier
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Dec 2024
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001492674
- Issuer location
- Lexington, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of T2 Biosystems, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Jacob Safier
Disclosed value leader
CR Group L.P.
Comparable rows
2/19
Latest evidence
31 Dec 2024
13D/G
3/4/5
Lead comparable stake: 5.3%
17 rows are not safely comparable across share classes.
13D/G row: Jacob Safier
Showing 1-8 of 19 holder rows.
Quick read
Jacob Safier leads the comparable SEC ownership view at 5.3%.
2 of 19 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Jacob Safier's linked filing trail.
Comparable ownership
Top 2
Jacob Safier
5.3%
JSAF Holdings, LLC
5.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 19 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Jacob Safier |
13D/G
Safier Jacob
|
5.3%
|
$165,000
1,500,000 shares
|
$0 | 31 Dec 2024 |
| JSAF Holdings, LLC |
13D/G
Safier Jacob
|
5.3%
|
$165,000
1,500,000 shares
|
$0 | 31 Dec 2024 |
| CR Group L.P. |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$740,995
4,732,765 shares
mixed-class rows
|
— | 09 May 2024 |
| GOLDMAN SACHS & CO. LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$661,749
4,201,582 shares
|
— | 24 Mar 2020 |
| Adrian M. Jones |
3/4/5
Director
|
—
class O/S missing
|
$661,749
4,201,582 shares
|
— | 24 Mar 2020 |
| Aparna Ahuja |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
$94,500
600,000 shares
|
— | 20 Feb 2022 |
| John McDonough |
3/4/5
Director
|
—
mixed-class rows
|
$94,241
598,353 shares
mixed-class rows
|
— | 01 Jul 2021 |
| John J. Sperzel III |
3/4/5
Chairman, President & CEO, Director
|
—
mixed-class rows
|
$77,238
490,400 shares
mixed-class rows
|
— | 04 Nov 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 28 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to T2 Biosystems, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
CR Group L.P.
Net 12M change
$0
Latest report
04 Nov 2024
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| CR Group L.P. | 10%+ Owner | $740,995 | Mixed | 09 May 2024 | ||
| GOLDMAN SACHS & CO. LLC | 10%+ Owner | $661,749 | Mixed | 24 Mar 2020 | ||
| Adrian M. Jones | Director | $661,749 | Mixed | 24 Mar 2020 | ||
| Aparna Ahuja | Chief Medical Officer | $94,500 | Mixed | 20 Feb 2022 | ||
| John McDonough | Director | $94,241 | Mixed | 01 Jul 2021 | ||
| John J. Sperzel III | Chairman, President & CEO, Director | $77,238 | Mixed | 04 Nov 2024 | ||
| Michael Terrence Gibbs | General Counsel | $29,946 | Mixed | 04 Nov 2024 | ||
| Alec Barclay | Chief Operations Officer | $28,656 | Mixed | 08 Apr 2022 | ||
| John M. Sprague | Cfo | $28,372 | Mixed | 04 Nov 2024 | ||
| Brett A. Giffin | Chief Commercial Officer | $28,362 | Mixed | 04 Nov 2024 | ||
| John W. Cumming | Director | $5,513 | Mixed | 04 Nov 2024 | ||
| David B. Elsbree | Director | $3,999 | Mixed | 04 Nov 2024 | ||
| Laura Lee Adams | Director | $3,938 | Mixed | 04 Nov 2024 | ||
| Robin Toft | Director | $3,938 | Mixed | 04 Nov 2024 | ||
| Ninfa Saunders | Director | $3,938 | Mixed | 04 Nov 2024 | ||
| Seymour Liebman | Director | $3,938 | Mixed | 04 Nov 2024 | ||
| Thierry Bernard | Director | $1,153 | Mixed | 15 Sep 2023 |
Recent insider transactions for T2 Biosystems, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.